ROS1 and non-small cell lung carcinoma: According to the PROFILE1001 study, the objective response rate (ORR) of crizotinib for ROS1-positive NSCLC was 72%, with the median progression free survival (PFS) and median overall survival (OS) were 19.3 months and 51.4 months, respectively.